EMCrit FOAM Feed

EMCrit FOAM Feed

By Scott D. Weingart, MD FCCMScienceMedicineHealth & Fitness
Download on the App Store
  • Favorites

    1,064

    Followers

  • Latest release

    7 days ago

  • Typical duration

    29 min

    per episode

  • If it hooks

    52%

    finish an episode

Based on Podcast App listening data

All EMCrit FOAM Feed episodes

  • Podcast 114 – Post-Arrest Care in 2013 with Stephen Bernard – Part II
    I've been waiting for this one for a long time. I get to interview Dr. Stephen Bernard on the topic of post-arrest care.

     

    Professor Stephen Bernard
    Senior Intensivist, The Alfred Hospital
    Professor Stephen Bernard is a senior Intensive Care Physician at the Alfred Hospital and Director of Intensive Care at Knox Private Hospital in Victoria, Australia. He is also Medical Advisor to Ambulance Victoria.

     

    Last Week, I posted Part I of this interview on Post-Arrest Care 2013
    This is Part II.

    My discussion with Dr. Bernard was based on a talk he gave at the Australasian College for Emergency Medicine

    Photo by Brian Burns
    MAP Goals
    SBP of 120 mm hg? The paper was just published ahead-of-print

    The other paper Dr. Bernard Mentioned is Gaieski et al. (Resuscitation 2007;73:29-39)
    Sedate
    If cooling to 36, it is a lot easier to get away with standard sedation practice as the hypothermia-slowed metabolism is no longer a big problem
    Cath lab with ECMO or LUCAS2 for refractory arrest
    It can be done! And if we can do it, is "stay-and-play" on scene still a good strategy?
    CHEER trial (CPR, Hypothermia, ECMO and Early Reperfusion)
    CHEER Trial Protocol

    15 F arterial cath and a 17-19 F venous catheter under ultrasound guidance, with the only pause during compressions being the initial vessel puncture and 1st wire advancement
    Intraarrest Hypothermia?
    The animal data look good, but need human trials that show benefit. If you do it, then these patients may need a deeper degree of hypothermia (33 C?).
    Prehospital Hypothermia and is Quicker Better?
    Dr. Bernard's trial did not show benefit for prehospital cooling [cite source='pubmed']20679551[/cite]

    and the in-press study by Kim et al. showed the same [cite source='pubmed']24240712[/cite]
    More from Steve can be found at the EDECMO Podcast Site
    Now, on to the Podcast...
    20 min
  • Podcast 113 – Post-Cardiac Arrest Care in 2013 with Stephen Bernard – Part I
    I've been waiting for this one for a long time. I got to interview Dr. Stephen Bernard on the topic of post-cardiac arrest care.

    Professor Stephen Bernard
    Professor Stephen Bernard is a senior intensivist at the Alfred Hospital and Director of Intensive Care at Knox Private Hospital in Victoria, Australia. He is also Medical Advisor to Ambulance Victoria. Dr. Bernard was the lead author on one of the original establishing studies for post-arrest temperature management.

     


    My discussion with Dr. Bernard was based on a talk he gave at the Australasian College for Emergency Medicine

    Photo by Brian Burns
    Maintain 36 C for 24 Hours
    Dr. Bernard and the Alfred Hospital in Australia are moving to the protocol outlined in the TTM trial
    Is there anyone who still deserves to be cooled to 33 C?
    Dr. Bernard feels patients that get intra-arrest cooling may still benefit until we have further trial results.
    Neuro-Prognosticate as per the protocol in the Nielsen trial
    Chris Nickson summarized the Neuro-Prognostication Protocol wonderfully
    Time Zero Prognostication
    It is tough. Unwitnessed asystole is probably one situation in which you can choose a palliative route if the situation otherwise supports it.
    Pt should be taken to a 24/7 cardiac interventional center
    This doesn't necessarily mean the patient needs to go to the lab immediately, they just need to be able to go when needed
    Lower FiO2
    Maintain an SpO2/SaO2 between 90-95%
    Normal PaCO2
    No hypocapnea, Perhaps slight hypercapnea
    Tune in Next Week for Part II of the Interview
    More on the TTM Trial

    * My initial Wee
    * A quick interview with Jon Rittenberger

    The Thoughts of Others
    https://twitter.com/JAMyburgh/statuses/402940221630603264

    https://twitter.com/JAMyburgh/statuses/403351251791781888
    More from Steve can be found at the EDECMO Podcast Site
    Now, on to the Podcast...
    21 min
  • Podcast 112 – A Response to the Marik Sepsis Fluids Lecture


    Last week I posted a lecture an incredible by Paul Marik on Fluid Management in severe sepsis. The lecture is the equivalent of a bucket of ice water poured over your head. Now let's give you a towel and discuss.
    Want to add a journal club to this flipped classroom?
    Then read these pieces in Critical Care:

    * Bellomo on Norepinephrine and the Kidney
    * Rethinking Resus Goals by Dunser
    * Response: Rethinking Resus Goals by Marik and Bellomo
    * Pharmacodynamic Analysis of a Fluid Challenge (Crit Care Med 2016;44:880)

    The Low-Fluid Volume Early Pressor Experiment has Already Been Tried
    It was called standard care 15-20 years ago--patients did not do all that well.
    Should we Increase DO2?
    We know from that shooting for supranormal DO2 is actually harmful. The original goal-directed therapy trials did not pan out and this may be why.

    There is definitely a group of Severe Sepsis patients that are receiving inadequate oxygen delivery. I have treated these patients; I have documented ScvO2s in the 50's and 60's on initial check in a EGDT-type algorithm.

    Far more commonly, patients are in pure vasodilatory shock (Jones' trial patients). The latter fact doesn't disprove the former. Using the studies demonstrating the deleterious effects of shooting for above normal delivery doesn't say anything about normalizing patients with low delivery.
    Marik's Goals

    * Achieve adequate perfusion pressure
    * Improve microcirculatory flow
    * Limit Tissue Edema

    All right on point; how do we get there is the question.
    Rivers Trial as a Waterfall?
    This is not actually what that trial showed. And the way CVP was used was not actually debunked by the 7 mares article (Note: I'm not advocating you use CVP, I'm just pointing this out! We have better ways to accomplish assessing fluid responsiveness so CVP should be sent to the junk bin)

    I will make the utterly blasphemous statement that Dr. Rivers and Dr. Marik are actually in near-complete agreement if you followed both of their protocols explicitly in the ED.
    MAP and Association to Survival
    Not sure what this is proving: both groups (the flow-optimizers and the desert-inducers) believe in shooting for MAP goals. Patients in whom it is impossible to get the MAP up will die more frequently.
    But is it Flow or Pressure that Matters?
    I must say, I am still in the tissue flow camp
    On to the Glycocalyx
    Now this is where stuff gets really interesting. Every day, there is increasing research and more publications on the fundamental role of the vascular glycocalyx. But how do we integrate this clinically?

    Chris Nickson tweeted this amazing lecture from Rob Wise. It will explain the Glycocalyx in 5 minutes. It lives on Life in the Fast Lane.



     

    Now as to its relation to fluids in sepsis, we are being told hypervolemia is bad. But if the fluids are leaking from the vascular space are we ever seeing hypervolemia in the vasculature or is the problem whole body volume overload--not if we believe BNP/ANP are the root of the problem, they only respond to vasculature fluids. If we are doing a fluid responsiveness strategy, we should not be seeing the vascular overload.

    Do balanced vs.
    31 min
  • Five Minutes with Jon Rittenberger on the TTM Trial


    Just posted a wee on the game-changing TTM Trial

    Managed to get Jon Rittenberger, MD on the line to discuss the implications. Jon wrote the editorial that accompanied the TTM trial and he is an accomplished Resuscitationist and a clinical leader for the U. Pitt post-arrest management team.

    Here are Jon's thoughts on what we should do with this trial tomorrow. I add my own opinion at the end. In the next couple of weeks, you'll hear from Stephen Bernard to get his take on the study.

    The 2nd article mentioned by Jon is this one:

    Kim, F et al. Effect of Prehospital Induction of Mild Hypothermia on Survival and Neurological Status Among Adults With Cardiac Arrest A Randomized Clinical Trial JAMA 2013

    Prehospital hypothermia in this study and the Bernard trial has not seemed to pan out. Intra-arrest is still in play however.
    My Take as of Now







    * In the setting of advanced post-arrest care, active temperature management, and protocolized neuro-prognostication; the TTM trial demonstrated no significant outcome difference or trend towards outcome difference when patients were cooled to either 33 or 36C
    * Hemodynamics were poorer in the 33C group (This was not mismatching, SOFA-C same on day 1 and much worse in 33C group on day 3; this was a secondary outcome and therefore the study can't demonstrate if this was a significant finding) [Table S2 Supplement]
    * Complications were less frequent in the 36C group
    * A majority of patients are probably best managed at or near 36C
    * In the neurocritical care literature, 35C seems to offer moderation of intracranial pressure
    * At Janus General, we will target a temperature range between 35-36C for our V-fib, V-tach, and PEA patients in whom we are pursuing an aggressive treatment path
    * Unwitnessed asystolic arrest patients were left out of the HACA, Bernard, and TTM trial. In this group there is little guidance and it may be reasonable to continue cooling to 33C as this group is most likely to have the most severe post-arrest neurologic injury.







    Interview with the Lead Author of Trial from the ICN
    Matt MacPartlin interviewed Niklas Nielsen, the author of TTM. He is joined by Anders Aneman, one of the local site investigators to discuss this game-changing study.
    Other Thoughts
    See this great post from the folks at the Intensive Care Network as well.

    The folks at St. Emlyn's offer a  more cautious approach.
    Updates
    JAAM-OHCA TTM Trial
    Now on to the Wee...
    6 min
  • EMCrit Wee – The Targeted Temperature Trial Changes Everything


    The TTM Trial was just published today in the NEJM (Nielsen et al. Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest NEJM 2013;epub Nov 17, 2013)

    For my take and the take of Jon Rittenberger, come to the 2nd TTM Post

    but even more important is to hear from the primary author himself: Niklas Nielsen on the TTM Trial
    Study Design
    International multicenter RCT

    Inclusion criteria: Age >= 18 years, out-of-hospital cardiac arrest of presumed cardiac cause, unconsciousness (Glasgow Coma Score <8) after sustained return of spontaneous circulation (ROSC) (20 minutes of circulation).

    Exclusion criteria: Conscious patients, pregnancy , out-of-hospital cardiac arrest of presumed non-cardiac cause, cardiac arrest after arrival in hospital, known bleeding diathesis, suspected or confirmed acute intracranial bleeding, suspected or confirmed acute stroke, temperature on admission <30°C, unwitnessed asystole, persistent cardiogenic shock, known limitations in therapy, known disease making 180 day survival unlikely, known pre-arrest cerebral performance category 3 or 4, >240 minutes from ROSC to randomisation.

    Primary outcome: Survival to end of trial (at least 180 days).

    Secondary outcomes: Composite outcomes of all-cause mortality and poor neurological function (Cerebral Performance Category (CPC) 3 and 4 and modified Rankin Scale (mRS) 4 and 5) at 180 days. All - cause mortality and CPC and mR S at 180 - days. Adverse events: Bleeding, pneumonia, sepsis, electrolyte disorders, hyperglycaemia, hypoglycaemia, cardiac arrhythmia, renal replacement therapy.

    Tertiary outcomes: Complete neurological recovery. Best neurological outcome during trial perio d. Quality of life according to SF - 36. Biomarkers at 24, 48 and 72 hours

    Intervention: The core body temperature will be set as quickly as possible at the predefined target temperature, according to intervention allocation, with 4°C intravenous solutions, 43 ice - packs 8, 44 and commercially available cooling devices 45 at the discretion of the treating physician . The target core temperature is then maintained for 24 h. After the maintenance period core temperature is gradually raised to normothermia of 37°C during 8 hours with a rewarming rate of 0.5°C/hour in both groups. Body temperature is then maintained at normothermia 37 ±0.5°C until 72 hours from sustained ROSC in both treatment groups, as long as the patient is in the ICU, using pharmacological treatment and temperature management systems when applicable

    See all of the nitty-gritty in the appendix
    rewarmed at 0.5 C/hr and then induced normothermia (37.5 C) for 36 hrs post arrest

    Nonblinded to temp allocation, but neuro assessment was blinded

    fluids icepacks surface and intravasc cooling-- 1/4 intravasc and rest surface
    900 pts give 90% power to detect 20% difference
    80% shockable, 12% asystole
    Table S2 - SOFA-C Scores in the first 72 hours



    *SOFA denotes Sequential Organ Failure Assessment, SOFA-C denotes the cardiovascular subcomponent of the SOFA score. SOFA-C=0 No need for inotrope or vasopressor, mean arterial pressure (MAP) > 70mmHg, SOFA-C =1 MAP < 70mmHg, SOFA-C=2 any dose of dobutamine or dopamine <5 ìg/kg/minute,
    3 min
  • Podcast 111 – Fluids in Sepsis, A New Paradigm – Paul Marik

    Dr. Paul Marik is a renowned intensivist and a confirmed critical care skeptic. He has broken down many myths such as the use of CVP for volume assessment. I recorded a lecture he gave to the Sepsis Collaborative I co-chair. It is an amazing lecture.
    I agree with some of it and have quibbles with other parts, but it is a must-listen. In one week, I will publish a wee with the areas I see differently; in the interim think about your own viewpoint so that we can discuss it all in the comments.
    Dr. Marik's Previous Visits to EMCrit

    * CVP and Fluid Assessment
    * Maybe Groin Lines Aren't that Bad

    Dr. Marik's Updated Hemodynamic Management Flowsheet


     
    Now on to the Podcast...
    52 min
  • SMACC Back 3 – Simon Carley on Leadership


    Now I should be doing a SMACC Back on Roger Harris' talk on the Right Heart as he surely cast a gauntlet in my path, but that would probably just encourage him : ). Instead, lets talk about...
    Simon Carley on Educational Leadership and Subversion
    This SMACC-Back deals with Simon Carley's lecture from SMACC 2013. If you haven't seen it yet, watch now--it is incredibly good:



    The line that resonated with me was,
    The first principle of Leadership is Excellence. The most important thing for an educational leader is that they are clinically credible. "Those that can't do--teach," is crap in medicine.
    So utterly true!

     

    Tangentially, one of my colleagues recommended a book to me entitled, Multipliers: How the Best Leaders Make Everyone Smarter.



    Wow, what a horribly misguided tome. To hear why I think this, listen to the wee.
    Get your SMACC 2014 Abstracts in ASAP
    The closing date for abstracts for SMACC is Friday the 22nd of November

    Be part of the action!

    Submit here.
    Now on to the SMACC Back...
    8 min
  • Podcast 110 – Exsanguinating Hemorrhage from Mid-Face Fractures


    Just got back from Toronto, where I learned about Chubby Bunny.

    Chubby Bunny by Derby

    But what we are actually going to talk about today is the management of Severe Hemorrhage from Mid-Face Blunt Trauma
    Algorithm
    Ann Plast Surg 2012;69:474


    Take the Airway
    Suction-as-you-go ETT Set-up

    Partner Suction a la Strayer

    These airways are all Cricon 3
    Anterior Packing
    I use Rapid-Rhino 5.5 cm but you go with whatever you are comfortable with. Soak it in STERILE WATER, not saline despite what i blathered in the audio (Thanks Brent!)
    Posterior Packing
    We use foleys in preference to commercial devices for standard epistaxis. This series explains why: (Injury. 2003 Dec;34(12):901-7. Complications with use of the Epistat in the arrest of midfacial haemorrhage.)

    Use 12 - 14F (or whatever you got)

    Witness passage into the posterior pharynx from both foleys with laryngoscope

    Inflate a smaller volume first (6-8 mL) and then apply traction until it wedges, this allows the balloon to wedge in the posterior choana

    Inflate to 20 ml

    Apply traction

    I use the system at the end of this video on Blakemore Passage

    Reapply the anterior packs bilaterally
    Temporary Fracture Fixation


    Image from Injury  Volume 34, Issue 12, December 2003, Pages 901–907 Holmes et al. From that article, "When there is a mid-palatal split, however, this haemostatic technique will possibly fail and additional measures will be required to achieve haemostasis. The split palate should be stabilised with a transpalatal circumdental wire , before placing packing."
    Angiography
    IR of the internal maxillary is usually what is needed

    May also be branches of ethmoidal in skull base fx
    TXA for Epistaxis
    EM Lit of Note's Review
    McKesson Oral Prop?
    EMJ 2010; 27 :156 e 158. doi:10.1136/emj.2008.070219

    Anyone know about this? Comment in the show notes.
    Additional References


    * Case Discussion (Ann Plast Surg 2--1;46:159)
    * Case Series on IR (J Trauma 2003;55:74)
    * Another Case Series on Management (J Trauma 2008;65:994)
    *  A Decade's experience with balloon tamponade fro traumatic hemorrhage (The Journal of Trauma: Injury, Infection, and Critical Care Issue: Volume 70(2), February 2011, pp 330-333)

    19 min
  • Practical Evidence 013 – ACEP Management of Asymptomatic Blood Pressure 2013


    We discuss the management of asymptomatic markedly elevated blood pressure as evaluated by the ACEP Clinical Policies Committee in Sept 2013.
    The Policy
    ACEP Management of Asymptomatic HTN 2013
    The Questions and the Recs


    In ED patients with asymptomatic elevated blood pressure, does screening for target organ injury reduce rates of adverse outcomes?

    Patient Management Recommendations

    Level A recommendations. None specified.

    Level B recommendations. None specified.

    Level C recommendations.

    * In ED patients with asymptomatic markedly elevated blood pressure, routine screening for acute target organ injury (eg, serum creatinine, urinalysis, ECG) is not required.
    * In select patient populations (eg, poor follow-up), screening for an elevated serum creatinine level may identify kidney injury that affects disposition (eg, hospital admission).

     

    In patients with asymptomatic markedly elevated blood pressure, does ED medical intervention reduce rates of adverse outcomes?

    Patient Management Recommendations

    Level A recommendations. None specified.

    Level B recommendations. None specified.

    Level C recommendations.

    * In patients with asymptomatic markedly elevated blood pressure, routine ED medical intervention is not required.
    * In select patient populations (eg, poor follow-up), emergency physicians may treat markedly elevated blood pressure in the ED and/or initiate therapy for long-term control. [Consensus recommendation]
    * Patients with asymptomatic markedly elevated blood pressure should be referred for outpatient follow-up. [Consensus recommendation]

    What is EMCrit Drinking?

    Now on to the Podcast...
     

    11 min
  • Podcast 109 – Mind of the Resuscitationist from SMACC 2013

    This lecture was from the final day of SMACC 2013. It was based on a case I saw at Janus General Hospital.

    [vimeo 76743429 w=620]
    Blakemore Placement
    In the lecture I talk about a life-saving Blakemore Tube placement. I suspect some of you may need a reminder of the intricacies of this device, so I made a video and cheat-sheet.
    Now on to the Podcast...
     
    18 min